Diplomat Announces 4th Quarter and 2015 Year End Financial Results; Provides Initial 2016 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Leerink Partners Cuts Price target on Diplomat Pharmacy (DPLO) Following Weak EPS Guide
March 1, 2016 7:23 AM ESTLeerink Partners maintained an Outperform rating on Diplomat Pharmacy (NYSE: DPLO), and cut the price target to $35.00 (from $40.00), following the company's 4Q. DPLO reported revenue of $987M, ahead of consensus' $970M. Adjusted EPS of $0.21 beat the consensus of $0.20. 2016 guidance calls for total revenue of... More
Diplomat Pharmacy (DPLO) Tops Q4 EPS by 1c
February 29, 2016 4:16 PM ESTDiplomat Pharmacy (NYSE: DPLO) reported Q4 EPS of $0.21, $0.01 better than the analyst estimate of $0.20. Revenue for the quarter came in at $987 million versus the consensus estimate of $969.7 million.
GUIDANCE:
Diplomat Pharmacy sees FY2016 EPS of $0.84-$0.89, versus the consensus of... More
